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Summary
Vaccines against human breast cancer are an unfulfilled promise.
Despite decades of promising preclinical and clinical research, no vaccine is currently available for breast cancer patients. Preclinical research has much to do with this failure, because early mouse models of mammary carcinoma did not mirror the molecular, cellular, antigenic and immunological features of human breast cancer. The advent of HER-2 transgenic mice gave impulse to a new generation of cell and DNA vaccines against mammary carcinoma, that in turn led to the definition of significant antigenic (oncoantigens) and cellular (cancer-initiating cells, preneoplastic lesions, incipient metastases) targets.
Future preclinical developments will include the discovery of novel oncoantigens in HER-2-negative mammary carcinoma and the targeting of activated HER-2 molecular variants. Translation to clinically effective vaccines will be fostered not only by new preclinical model systems, but also by the possibility to conduct veterinary vaccination trials in companion animals.
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Preclinical models of mammary carcinoma for tumor immunology
Research on mammary carcinoma is inextricably interwoven with the history of preclinical models, starting with the development in the 1920s of the C3H mouse strain, selected for a high incidence of mammary tumors. It is a history that illustrates very well some critical issues of preclinical models in general [1] . On the one side, the C3H model of mammary carcinoma, caused by the mouse mammary tumor virus (MMTV), is no longer regarded as a reliable model for human breast cancer, which is not caused by viruses. On the other side, the discovery of MMTV and the analysis of its oncogenic activity were key steps in the development of molecular oncology, eventually leading to the discovery of various oncogenes.Today MMTV continues to contribute to mammary carcinoma preclinical models, because its (relative) tissue specificity was harnessed to drive the expression of oncogenes and other genes in the mammary gland, and many transgenic mice prone to mammary carcinoma in use today were designed using (non-coding) MMTV sequences [2] .
Cell lines
In addition to the viral etiology, MMTV-infected mice have shortcomings as model systems for vaccination studies. Obviously viral antigens are expected to dominate or otherwise distort the immune responses elicited by vaccines, a further difference with human breast cancer.
Furthermore, tumor onset and growth required repeated pregnancies and lactation, altogether making MMTV-infected mice a poorly reproducible and cumbersome system for immunological studies [1] . Starting in the 1970s, immunological research resorted to the use of cell lines derived from mammary carcinomas, for example from occasional spontaneous carcinomas, arising in "retired breeders", i.e. old multiparous females, of MMTV-free strains, like BALB/c [3] . These cell lines were thought to reproduce the low immunogenicity of human tumors, thus giving rise to more faithful preclinical models for vaccination studies. While it is true that cell lines like TS/A were poorly immunogenic, in retrospect they were not exempt from the "viral sin", because in many instances the immunodominant antigens were later shown by molecular studies to be related to endogenous retroviral sequences [4, 5] .
Genetically modified mice
The advent of genetically modified mice has revolutionized biomedical research, allowing the establishment of preclinical models of human diseases for which no equivalent spontaneous mouse pathology existed or was not a faithful model of human disease, as is the case of mammary carcinoma.
Immunological studies focused on HER-2 transgenic mice, that offered for the first time a preclinical model of high penetrance mammary carcinogenesis caused by an oncogene known to be involved in human breast cancer, and at the same time offered an attractive immunological target. Many different HER-2 transgenic mouse lines were produced over the last 25 years [6] thus it is important to understand their characteristics in relation to human breast cancer [7] . Under this respect it should be noted also that our knowledge of human tumors has evolved in parallel, leading to different perceptions of what can be considered a good animal model. Think for example of point mutations, which for many years were thought to be almost non-existent in human pathology, whereas next generation sequencing is bringing to light a small but consistent percentage of tumors driven by mutant HER-2 [8] .
Earlier transgenic mice carried a mutant rat HER-2 (the HER-2 oncogene was originally cloned in rat and called neu) transgene controlled by MMTV long terminal repeat (LTR) sequences [2, 9] and displayed a very aggressive mammary carcinogenesis, with progressive carcinomas in all ten mammary glands within the first semester of life. The same promoter was then used to drive the wild-type (i.e. non-mutated) rat HER-2 gene in atransgenic model with a milder carcinogenesis, displaying carcinomas in 2-4 mammary glands by one year of age [10] .
The following step was the replacement of the rat oncogene with the human ortholog, thus obtaining a transgenic mouse in which anti-human HER-2 antibodies and analogous therapeutic agents could be directly tested [11] .Latest developments were driven by the discovery in humans of activated HER-2 variants, such as the Delta16 isoform or the p95 truncation, that were shown to be highly oncogenic in transgenic mice, ultimately giving rise to novel model systems that reproduce the aggressiveness of those based on the mutant rat oncogene [12] [13] [14] .
Widespread interest in these transgenic models of mammary carcinogenesis led to the developments of countless mouse lines of different genetic backgrounds, bearing different oncogenes, different promoters, and combinations of HER-2 with many other cancer genes [6, 7] . We will restrict ourselves to some basic key elements based on our experience for the choice of a system for preclinical vaccine studies.
1. Tumor penetrance is the first element. Many interesting transgenic lines with a low tumor incidence make extremely cumbersome model systems and mandate the use of very large experimental groups. Whenever possible prefer models with a nearly 100% incidence.
2. Tumor latency is another key. Experiments in transgenic mice take a long time in comparison to those with transplanted cell lines, and if your vaccine effectively prevents tumors you will need even longer observation times. Models in which the first tumors appear after one year of age make the life hard for a successful vaccinologist. Apart from practical considerations, it should be also kept in mind that a long tumor latency in a mouse carrying an oncogene means that additional genetic events are required for tumor onset, which could be either an advantage or a disadvantage, depending on the type of research project.
3. Aggressiveness is not to be feared. When we started the study of anti-HER-2 preventive vaccines, we thought that a mouse prone to the onset of invasive carcinomas in all mammary glands was a daunting prospect, however our experience showed that powerful vaccines could completely prevent tumor onset in these mice [15, 16] , provided that vaccinations started at the right time [17] , which brings us to the following point. 4 . Timing is of the essence. As transgenic mice reproduce tumor progression, the effectiveness of cancer vaccines is frequently dependent on vaccination schedules taylored on the stages of tumor progression (e.g. atypical hyperplasia, in situ carcinoma, angiogenic switch, wtc.) in the model in use. Fortunately, a key advantage of transgenic models of mammary carcinogenesis is the repeatability (with possible variations) of tumor progression.
Human-in-mouse systems
Until recently, the only way to investigate human immune responses to vaccines, short of actually immunize human subjects, was the in vitro study of immune cell reactivity, clearly a suboptimal way to investigate the complexities of in vivo responses. Paradoxically, the advent of highly immunodeficient mouse models has considerably improved not only the study of human tumor biology, but also that of human immunology [18] .
Residual immune responses, in particular NK cells, of older immunodeficient mouse models, such as athymic nude mice, considerably impair the survival of implanted human cells, both normal and neoplastic [19, 20] .
A key development was the knockout of the common gamma subunit of interleukin receptors (Il2rg), that blocks NK development. Mouse models combining T and B cells deficiencies with Il2rg knockout, such asRag2 -/-;Il2rg -/-(BRG) or NOD-scid-gamma (NOG) mice, allow for the first time the study of HER-2+ human breast cancer dissemination, and at the same time can be reconstituted with human stem cells that give rise to a functional immune system [21] . We have recently shown that, in reconstituted BRG mice, the human immune system can respond to vaccines against human HER-2 with the production of specific antibodies and possibly other immune responses that hamper the metastatic spread of human tumor cells [22] . Will the pet lead to a breakthrough in the fight against cancer? The premises are good, but there is still much work to do.
Natural occurring cancers in pet animals

Vaccination strategies and protective immune responses
Vaccines for immunoprevention of mammarycarcinoma
Studies of mammary carcinoma preventive vaccines in HER-2 transgenic mice not only contributed to the notion of non-viral cancer immunoprevention, but also highlighted various important concepts in tumor immunology. We have reviewed this field in the recent past [33] [34] [35] ,therefore here we will focus on general principles relevant to vaccine development, summarizing the most important conclusions.
Effective vaccines were able to completely block the development of mammary carcinoma in HER-2 transgenic mice [15, 16, 36] . Different vaccine formulations, such as cell-based and DNA vaccines were equally effective [37] .
Common vaccinological properties were the use of powerful adjuvants and intensive vaccination schedules. Microscopic analysis revealed that cancer progression was indefinitely "frozen" at the stage of hyperplasia by vaccination, and that HER-2 expression was greatly down modulated [38] .
Immunological studies showed that protective immune responses elicited by vaccines were mainly based on helper T cell cytokines, in particular gamma interferon, and anti-HER-2 antibodies of Th1 isotypes (like IgG2a and IgG2b in the mouse), whereas cytotoxic T cell responses did not play a relevant role [39] . Antibodies were the effectors of long-term protection, and titers after the first cycles of vaccination predicted long-term protection from tumor development [37] .
Therapeutic vaccines
Basically most preclinical vaccination experiments targeted "local" mammary carcinomas. Countless experiments were performed over the years using almost any conceivable vaccine design and formulation, and the ensuing publications attest the attainment of several positive results with many different vaccination approaches [40] . A comprehensive review would be at once humongous and useless. We would rather provide a critical appraisal of some key issues related to preclinical models, because the continuing lack of clinical impact vis-à-vis the huge amount of positive preclinical results could suggest that past and current preclinical models are part of the problem.
The first thing to stress is that the model system used for preclinical testing is an important variable, and that there are innumerable variations that can directly impact the results. In general one must ask up front how far removed from the human condition is the preclinical model. The trade-off is between "simple" models that are quite different from clinical situations and cumbersome systems that more closely mirror human pathology and therapy.
The simplest thing to do is to perform a classical vaccination-challenge experiment: tumor-free mice are first vaccinated, and then challenged subcutaneously with a syngeneic mammary carcinoma cell line. At the opposite end of the spectrum is therapeutic vaccination administered to a mouse bearing a spontaneous ("autochthonous") mammary carcinoma or, even better, the same mouse undergoing surgical removal of the primarytumor followed by therapeutic vaccination for prevention or therapy of distant metastases [41] .
Being guilty of using, over the years, practically every variation of preclinical models for studying mammary carcinoma vaccines, we can only practice non-directive counselling. the efficacy of an anti-HER-2 vaccine followed a saddle-like curve related to tumor development and progression [35] . Maximal efficacy was obtained in preventive protocols starting before tumor onset, followed by a precipitous loss of activity against established tumors [17, 36] . However the same vaccine was again active against metastasis development, demonstrating that preventive oncologists are right when they designate as "tertiary cancer prevention" what medical oncologists call adjuvant therapy [43] .
4. Transgenic models of mammary carcinogenesis can be unsuitable for studies of autochthonous metastases [42] . Aggressive mammary carcinogenesis, in some cases leading to the continuing development of independent carcinomas in all mammary glands, can prevent meaningful studies of metastasis therapy in the absence of growing primary tumors.
5. Studying naturally occurring tumors in pets is likely to provide a valuable perspective that is distinct from that generated by studying rodent models alone before first in-human studies [44] . An increasing number of trials is ongoing in various Veterinary Teaching Hospitals, both in Europe and in the USA, and promise to solve many problems of mouse pre-clinical models.
Targeting of cancer stem cells
To date, bulk tumor masses with heterogeneous populations of cancer cells have been used as a source of potential drug or vaccination targets.
However, human tumors are composed of heterogeneous cancer cell subpopulations that differ with respect to proliferation, differentiation, and ability to initiate daughter tumors. The slowly dividing cancer initiating cells endowed with stem cell properties, like the capacity to self-renew and to reestablish tumor heterogeneity, appear to be the sub-population responsible for tumor progression, metastatization, resistance to therapy, and tumor recurrence [45] .
The notion that cancer stem cells may play a major role in cancer progression has important implications. It may account for most of the difficulties of current treatments in eradicating malignant tumors. Those treatments designed to shrink the bulk of a tumor may fail to eliminate the small fraction of cancer stem cells endowed with chemo-and radio-resistance and immune-evasive features [46] . In some cases, the vaccine-induced response against antigens identified in the bulk of the tumor, may even drive the selection of cancer stem cells and promote tumor growth [47] . Instead, for therapy to be more effective, debulking of differentiated tumors must occur followed by targeting of the remaining surviving often quiescent cancer stem cells. A recent report actually demonstrated that a vaccine done of dendritic cells primed with antigens derived from purified cancer stem cells induced a significant protective antitumor immunity in mouse models [48] .
The understanding of the pathways regulating breast cancer stem cell self-renewal, differentiation and tumorigenicity, and the identification of appropriate drug and vaccination targets may be critical in the development of effective breast cancer therapies [49] .
Target antigens
HER-2 is a superior target for mammary carcinoma immunotherapy, both in humans and in preclinical models. Why? In other words, is HER-2 endowed with specific features not shared by other tumor antigens? And can we derive general principles that will help in defining novel tumor antigens on a par with HER-2?
On the experience of cancer immunoprevention in HER-2 transgenic mice, we defined two key antigenic features of HER-2. Firstly, HER-2 was at the same time the driving oncogene of mammary carcinogenesis and the target antigen. In our model systems, HER-2 was necessary for tumor onset, and cell variants with low/absent HER-2 expression (observed only in vitro) displayed a simultaneous loss of tumorigenicity [50] . Secondly, downmodulation of class I major histocompatibility complex glycoproteins, an overly common human tumor phenotype [51] , was observed also in vivo in mammary carcinomas of HER-2 transgenic mice, indicating that T cell recognition of tumor cells could be severely hampered [52] .However, surface expression of HER-2 preserved immune recognition by antibodies, which in fact were the main immune effectors of protection from tumor onset [39] .
In other words, HER-2 is a good antigen because it is impervious to the two main causes of immunotherapeutic failure, antigen loss and MHC loss. A generalization of these concepts lead to the definition of a novel category of tumor antigens, that we named oncoantigens.
Oncoantigens
In the original definition, we called oncoantigens those tumor antigens that play a causal role in tumor development and are expressed on the cell surface [33] . More recently we revised the original definition to include further categories of promising antigenic targets having in common an oncogenic role [34, 35] . Class III oncoantigensare intracellular molecules controlling tumor growth.
In essence the oncoantigen concept affirms that molecules driving cancer are more persistent antigenic targets than "passenger" molecular alterations. Cancer progression and selective pressure exerted by therapeutic agents can result in a succession of different drivers over time, therefore the persistence of oncoantigens is to be understood in relative, not absolute terms.
However there will always be driving molecules to be targeted in a given stage of tumor development.
From an immunological perspective, the three classes define a hierarchy of effector mechanisms, because class Ioncoantigens (membrane) are targeted both by T cells and by antibodies, class II molecules (soluble) are only bound by antibodies, while class III (intracellular) can be recognized only by T cells in association with MHC molecules. Given the widespread of MHC loss in tumors [53, 54] , broadly speaking class I (and II) oncoantigens are more attractive, however also class III oncoantigens have been successfully targeted [55, 56] , and a possible role of antibodies even against these oncoantigens hiddeninside the cell has been recently hypothesized [57, 58] .
Discovery of novel oncoantigens -Preneoplastic lesions, differentiated tumor cells, cancer stem cells
The most important oncoantigen identified so far for breast cancer is Microarray transcription studies are a powerful instrument to identify potential oncoantigens on a genome-wide basis. We have generated a pipeline for oncoantigen identification based on the integration of gene expression data from mammary cancer-prone genetically engineered mice and human mammary cancer [60] . Mammary tissue samples are collected from mice of various ages, corresponding to different stages of tumor progression, from atypical hyperplasia to invasive cancer; total RNA is extracted and gene expression profiles are generated using genome-wide mouse arrays. Of the transcripts up-regulated going from pre-neoplastic lesions to overt cancer, only those that have an orthologue in humans, low expression in normal human tissues, and a high and homogeneous expression in human cancers are selected. The functional role of the corresponding molecules in fostering the transformed phenotype is investigated. Vaccines against these "putative"
oncoantigens are then generated to immunize cancer-prone transgenic mice and assess whether an effective immune response affecting tumor progression can be generated [61] .In this way several oncoantigens have been identified [34, 61] . Additional oncoantigens generated by specific mRNA isoform usage or represented by aberrant fusion products can now be identified using Next Generation Sequencing technology. Nevertheless tumor-derived, over-expressed miRNAs can be secreted outside of the cell and can be detected in the sera, thus representing a new class of diagnostic and prognostic biomarkers [66] . Their titration can be used to assess disease progression and the effectiveness of vaccination against oncoantigens.
Global miRNA deregulation has been shown in breast cancer [67] [68] [69] [70] while specific miRNAs have been associated with clinico-pathological features of breast tumors such as estrogen and progesterone receptor expression [71] , tumor grade [68] , vascular invasion or proliferation index [72] . Profiling studies have been mainly focused on miRNAs deregulated in primary breast cancer [70, 73] or in breast cancer cell lines [74] , while characterization of a deregulated miRNA expression profile in different tumor stages would permit to assess miRNA involvement in tumor progression. Using this type of approach, we have recently characterized the deregulated miRNA expression profile during tumor progression in mammary cancer-prone HER-2 transgenic mice. The miRNAs found down regulated during tumor progression and their putative targets are under investigation. miR-135a and miR-135b were found to be up-regulated during tumor progression [75] . While their involvement in breast cancer has never been described, by exploiting data on the expression of miRNAs in human breast cancers [70, 73] , the over-expression of miR-135b, but not miR-135a, appeared to be associated with poor prognosis. In addition, miR-135b overexpression in basal-like and estrogen-negative human tumor shown by this meta analysis fits in well with the notion that mammary tumors of our HER-2 trasngenic mice are similar to basal-like and estrogen-negative human mammary carcinomas [76] . Down-modulation of miR-135b in cancer cells from HER-2 transgenic mice revealed its major role in anchorage-independent growth and lung metastasis formation. MID1 and MTCH2 were identified and validated as putative miR-135b targets.
Vaccines and adjuvants
The efficacy of a vaccine rests on its ability to induce an effective antibody and cell-mediated immune response against the target antigen. Once triggered, immunity is kept at an efficacious protective intensity during the aging of the individual, both through natural re-stimulation or vaccine boosts. 
Proteins and peptides
Protein-and peptide-based antigen vaccines were among the first defined vaccines demonstrating both protective and therapeutic efficacy in animal models [40, 77] . genes, thus obtaining a single-component cell vaccine [83] . The results obtained with either formulation were similar.
The Triplex vaccine, when administered to young HER-2 transgenic mice was able to block indefinitely mammary carcinogenesis at the stage of atypical hyperplasia, preventing the development of mammary carcinomas and resulting in 100% survival at one year or more of age, when all nonvaccinated mice had already succumbed to tumors [15] .
The key elements of the complete protection afforded by the Triplex vaccine were defined through a large series of protocol variations, which were explored not only in vivo, butalso using a combination of in silico and in vivo approaches [84] .
The Triplex was the minimal combination yielding long-term
protection, all subsets of just one or two components significantly prolonged tumor latency, but did not prevent tumor development. intradermal or intra-muscularly by simple injection or through bio-ballistic methods or in vivo electroporation [34] . The latter is one of the most promising current technologies for DNA vaccine delivery [85] , that greatly impacts vaccine immunogenicity and efficacy by increasing antigen delivery up to a 1000 fold over naked DNA delivery alone, with improved in vivo immune response magnitude. Recently, a new strategy based on microneedles implantation into the skin of biodegradable polymer films containing DNA polyplexes and adjuvant molecules, has been tested with promising results [86] .
DNA vaccines directed against HER-2 have proven to be successful in the prevention of tumor growth in transplantable tumor models as well as in HER-2 transgenic mice [16, 34, 36, 40] .
In HER-2 transgenic mice DNA vaccines based on plasmids coding for the extracellular and transmembrane domain of rat HER-2 (RRT plasmids) effectively and persistently hamper the expansion of incipient tumors. This remarkable protection was correlated with the induction of anti-HER2
antibodies [16] . RRT plasmids efficacy fades away when they are administered to mice bearing advanced tumors [33, 35, 64] . A significant therapeutic effect was obtained only when RRT vaccination was associated with T regulatory cells depletion [17] , which, however, could also increase the risk of autoimmunity [87] . To obtain a stronger immune response and circumvent natural tolerance two new chimeric DNA vaccines (RHuT and HuRT) were constructed, encoding HER-2 extracellular and transmembrane domains composed in part by rat and by human sequences. RHuT encodes a protein in which the 410 NH2-terminal residues are from the rat HER2 and the remaining residues from human HER-2, while HuRT encodes a protein the first 390 NH2-terminal residues of which are from the human HER-2 and the remaining part from the rat HER-2. These chimeric plasmids combine the specificity, ensured by homologous portions, and tolerance break, ensured by heterologous portions [36] . We found that this combination effectively primes immune effector cells in tolerant hosts [34, 36] . In principle, this strategy of combining heterologous with self moieties can be applied to any oncoantigen that share high level of sequence identity and T cell epitopes to produce a potent DNA vaccine. 
DNA vs cell vaccines
Different vaccination technologies are only rarely compared head-tohead [90] .We have developed highly active cell and DNA vaccines against HER-2 in the same model systems [15, 16] , and we have also taken the opportunity to perform direct comparisons in the prevention of tumor development in transgenic mice [37] . The fundamental result was that both accepted that these heterologous prime-boosts are more immunogenic than homologous prime-boosts in vaccination against both infectious diseases [91] and cancer [92] . Moreover, it has been reported that vaccinated patients receiving subsequent chemotherapy exhibited significantly delayed tumor progression and longer survival relative to those receiving vaccinations without subsequent chemotherapy or those receiving chemotherapy alone. Improved clinical outcome appeared dependent on the specific combination of therapeutic vaccination followed by chemotherapy [95, 96] .
In pre-clinical models we have recently reported that vaccination against antigens expressed by vascular cells can sensitize clinically evident mammary carcinomas to a subsequent chemotherapy treatment [97] . DNA vaccination targeting angiomotin, one of the angiostatin receptors expressed by endothelial cells of angiogenic tissues [98] , induced an antibody response that alters the structure and the permeability of tumor vessels, resulting in vessel maturation and stabilization. These antibody-induced vessel alteration was effective both in halting the progression of clinically evident tumors and in making them more susceptible to chemotherapy, thanks to an enhanced tumor perfusion [97] . A similar effect was found in patients treated with a humanized monoclonal antibody neutralizing vascular endothelial growth factor (bevacizumab) [99, 100] .
Expert Commentary
The enormous amount of successful pre-clinical applications of cancer vaccines has not met a corresponding efficacy when translated into clinic. This fact is not limited to breast cancer, but is a generalized result [101] . These frustratingly slow progresses of anti-cancer vaccination are due to various weaknesses of the pre-clinical testing, such as the target antigen choice (not always the target was an oncoantigen) and the inadequacy of available animal models of human cancer [89] . Genetically engineered mouse models have significantly contributed to our understanding of cancer biology and treatment [18] . They have certainly proven to be better clinical models as compared to "instant cancers" obtained by injecting mice with transplantable tumors, or by bombarding mice with carcinogen doses higher than those that any human will ever encounter [102] . However, they still have significant limitations in modeling human cancer that the recently developed mice with a reconstituted immune system are not expected to easily solve. If we are going to beat cancer, we need a new path to progress [102] .
Naturally occurring pet tumors provide meaningful systems to study the complexity of human tumors in a far less artificial way. Using naturally occurring cancer in pet animals could also solve the ethical issues of animal experimentation. While medical research involving animals is sometimes controversial and misunderstood, experimentation in pets with naturally occurring cancer will provide benefits for both man and animals. Compared with humans, pets have compressed life spans, so the efficacy of a vaccine in improving survival can be determined relatively quickly [44] .
In conclusion, we believe that part of the failures of cancer vaccines in humans can be ascribed to the use of unfaithful preclinical models or, more precisely, to the use of models that were inappropriate for the preclinical development of cancer vaccines. The advent of genetically modified mice expressing human oncoantigens, and the possibility to move from experiments in mice to trials in cats and dogs provides a realistic preclinical framework for the development of vaccines against mammary carcinoma endowed with true translational potential.
Five year view
Until now HER-2 has dominated the scene of preclinical vaccine research in mammary carcinoma, not only because it is an excellent oncoantigen, but also because of the lack of promising antigenic targets in HER-2-negative tumors. Search strategies discussed here will lead to the discovery of oncoantigens in triple-negative and other subtypes lacking HER- 
Key Issues
• There is no approved vaccine for human breast cancer, despite decades of research. Early mouse models of mammary carcinoma, which do not mirror the immunology of human breast cancer, hampered the development of effective vaccines.
• The advent of HER-2 transgenic mice fostered the design of a novel generation of powerful anti-HER-2 vaccines, and led to the development of novel concepts in tumor immunity
• Different vaccine technologies, designs and protocols yielded excellent protection from HER-2-positive mammary carcinoma in mice. DNA vaccinationemerged as an eminently flexible and translatable technology.
• Highly immunodeficient mice reconstituted with a human immune system can be used to test vaccines against human tumors, however current models do not reconstitute the complexity of human tumor immunology.
• Oncoantigens are defined as tumor antigens causally involved in tumor onset and malignancy. Oncoantigens are optimal vaccine targets for the prevention of tumor onset and metastasis development.
• HER-2 is the prototypical oncoantigen of mammary carcinoma. The definition of search strategies combining preclinical and clinical systems areleading to the discovery of oncoantigens in mammary carcinomas lacking HER-2 overexpression.
• Activated HER-2 isoforms expressed in human breast cancer are a promising target for the development of novel vaccines.
• Preclinical development of innovative vaccines will find an optimal environment in novel genetically modified mice and in veterinary trials in companion animals.
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